drugset / Trial / NCT05795400
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Completed
50 enrolled
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RandomizedParallel-groupSingle-blindTreatment
Summary
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2025-05-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |